STOCK TITAN

Fosun International Receives the "ESG & Sustainability Award" and Two Other Prestigious Honors from Global Banking and Finance Review

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags
Fosun International (FOSUY) has been awarded three prestigious honors by Global Banking and Finance Review: Best Sustainable Development Company Asia 2025, Best CSR Company Asia 2025, and Holding Group Brand of the Year Asia 2025. The company's ESG strategy "Create IMPACT" focuses on six key areas: Innovation-driven, Mindful Operation, People and Partner Oriented, Advanced Governance, Climate and Planet Positive, and Transparency. Fosun maintains an MSCI ESG rating of AA and ranks in the top 5% among global peers in S&P Global's CSA. Notable achievements include their Rural Doctors Program supporting 25,000 doctors and benefiting 3 million rural families, and Henlius' HANSIZHUANG becoming the first PD-1 drug approved for ES-SCLC treatment in the EU. Fosun Pharma's artesunate injection has saved over 80 million severe malaria patients globally. The company operates across 35+ countries and joined the UN Global Compact in 2014, demonstrating commitment to sustainable global development.
Fosun International (FOSUY) ha ricevuto tre prestigiosi riconoscimenti da Global Banking and Finance Review: Migliore Azienda per lo Sviluppo Sostenibile in Asia 2025, Migliore Azienda CSR in Asia 2025 e Gruppo Holding Brand dell'Anno in Asia 2025. La strategia ESG dell'azienda, "Create IMPACT", si concentra su sei aree chiave: Innovazione, Operatività Consapevole, Orientamento a Persone e Partner, Governance Avanzata, Clima e Pianeta Positivi, e Trasparenza. Fosun mantiene una valutazione ESG MSCI di AA e si posiziona tra il 5% migliore a livello globale secondo la CSA di S&P Global. Tra i risultati più rilevanti vi sono il Programma Medici Rurali, che supporta 25.000 medici e beneficia 3 milioni di famiglie rurali, e HANSIZHUANG di Henlius, il primo farmaco PD-1 approvato in UE per il trattamento dell'ES-SCLC. L'iniezione di artesunato di Fosun Pharma ha salvato oltre 80 milioni di pazienti con malaria grave in tutto il mondo. La società opera in più di 35 paesi e dal 2014 fa parte del Global Compact delle Nazioni Unite, dimostrando il suo impegno per uno sviluppo globale sostenibile.
Fosun International (FOSUY) ha sido galardonada con tres prestigiosos premios por Global Banking and Finance Review: Mejor Empresa de Desarrollo Sostenible en Asia 2025, Mejor Empresa de RSC en Asia 2025 y Grupo Holding Marca del Año en Asia 2025. La estrategia ESG de la compañía, "Create IMPACT", se enfoca en seis áreas clave: Innovación, Operación Consciente, Orientación a Personas y Socios, Gobernanza Avanzada, Clima y Planeta Positivos, y Transparencia. Fosun mantiene una calificación ESG MSCI de AA y se encuentra en el top 5% a nivel global según la CSA de S&P Global. Entre sus logros destacan el Programa de Médicos Rurales que apoya a 25,000 médicos y beneficia a 3 millones de familias rurales, y HANSIZHUANG de Henlius, el primer medicamento PD-1 aprobado en la UE para el tratamiento de ES-SCLC. La inyección de artesunato de Fosun Pharma ha salvado a más de 80 millones de pacientes con malaria grave en todo el mundo. La empresa opera en más de 35 países y se unió al Pacto Global de la ONU en 2014, demostrando su compromiso con el desarrollo sostenible global.
푸순 인터내셔널(FOSUY)은 Global Banking and Finance Review로부터 2025년 아시아 최고의 지속 가능 발전 기업, 2025년 아시아 최고의 CSR 기업, 2025년 아시아 올해의 홀딩 그룹 브랜드 등 세 가지 권위 있는 상을 수상했습니다. 회사의 ESG 전략인 'Create IMPACT'는 혁신 중심, 신중한 운영, 사람 및 파트너 지향, 고급 거버넌스, 기후 및 지구 친화, 투명성 등 여섯 가지 핵심 분야에 중점을 두고 있습니다. 푸순은 MSCI ESG 평가에서 AA 등급을 유지하며 S&P 글로벌 CSA에서 글로벌 동종업계 상위 5%에 랭크되어 있습니다. 주요 성과로는 25,000명의 의사를 지원하고 300만 농촌 가정에 혜택을 주는 농촌 의사 프로그램, EU에서 ES-SCLC 치료를 위한 첫 PD-1 약물로 승인된 헨리우스의 HANSIZHUANG 등이 있습니다. 푸순 제약의 아르테수네이트 주사는 전 세계적으로 8천만 명 이상의 중증 말라리아 환자를 구했습니다. 회사는 35개국 이상에서 사업을 운영하며 2014년 UN 글로벌 콤팩트에 가입하여 지속 가능한 글로벌 발전에 대한 의지를 보여주고 있습니다.
Fosun International (FOSUY) a reçu trois distinctions prestigieuses de la part de Global Banking and Finance Review : Meilleure entreprise de développement durable en Asie 2025, Meilleure entreprise RSE en Asie 2025, et Groupe Holding de l'année en Asie 2025. La stratégie ESG de l'entreprise, "Create IMPACT", se concentre sur six domaines clés : Innovation, Opération Consciente, Orientation vers les Personnes et Partenaires, Gouvernance Avancée, Climat et Planète Positifs, et Transparence. Fosun détient une note ESG MSCI de AA et figure parmi les 5 % meilleurs au niveau mondial selon le CSA de S&P Global. Parmi ses réalisations notables, le Programme des Médecins Ruraux qui soutient 25 000 médecins et bénéficie à 3 millions de familles rurales, ainsi que HANSIZHUANG de Henlius, premier médicament PD-1 approuvé dans l’UE pour le traitement de l’ES-SCLC. L’injection d’artésunate de Fosun Pharma a sauvé plus de 80 millions de patients atteints de paludisme grave dans le monde. L’entreprise opère dans plus de 35 pays et a rejoint le Pacte mondial des Nations Unies en 2014, témoignant de son engagement en faveur d’un développement durable à l’échelle mondiale.
Fosun International (FOSUY) wurde von Global Banking and Finance Review mit drei renommierten Auszeichnungen geehrt: Bestes Unternehmen für nachhaltige Entwicklung Asien 2025, Bestes CSR-Unternehmen Asien 2025 und Holding-Gruppen-Marke des Jahres Asien 2025. Die ESG-Strategie des Unternehmens „Create IMPACT“ konzentriert sich auf sechs Schlüsselbereiche: Innovationsgetrieben, Achtsamer Betrieb, Menschen- und Partnerorientierung, Fortschrittliche Governance, Klima- und Planet-positiv sowie Transparenz. Fosun hält eine MSCI ESG-Bewertung von AA und gehört laut S&P Globals CSA zu den besten 5 % weltweit. Bedeutende Erfolge sind das Rural Doctors Program, das 25.000 Ärzte unterstützt und 3 Millionen ländliche Familien erreicht, sowie Henlius‘ HANSIZHUANG, das erste PD-1-Medikament, das in der EU für die Behandlung von ES-SCLC zugelassen wurde. Die Artesunat-Injektion von Fosun Pharma hat weltweit über 80 Millionen schwerkranke Malariapatienten gerettet. Das Unternehmen ist in über 35 Ländern tätig und ist seit 2014 Mitglied des UN Global Compact, was sein Engagement für nachhaltige globale Entwicklung unterstreicht.
Positive
  • Received three prestigious ESG and sustainability awards from Global Banking and Finance Review
  • Maintains MSCI ESG rating of AA and ranks in top 5% among global peers in S&P Global's CSA
  • Rural Doctors Program has supported 25,000 doctors and benefited 3 million rural families
  • First PD-1 drug (HANSIZHUANG) approved for ES-SCLC treatment in EU
  • Artesunate injection has saved over 80 million malaria patients globally with 400 million doses supplied
Negative
  • None.

HONG KONG, June 11, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine, Global Banking and Finance Review, that it has received three awards: "ESG & Sustainability Awards – Best Sustainable Development Company Asia 2025", "CSR Awards – Best CSR Company Asia 2025", and "Brand of the Year Awards – Holding Group Brand of the Year Asia 2025". These accolades underscore the market's recognition of Fosun's exceptional performance in ESG strategy, corporate governance, social responsibility, environmental protection, information disclosure, and stakeholder engagement.

Honoring Companies for Excellence in Business Performance and Sustainable Development

Global Banking and Finance Review highlighted that, after more than 30 years of development, Fosun has evolved into a global innovation-driven consumer group. As a global large-scale private enterprise, Fosun has pursued a core business-focused strategy, embraced innovation, and advanced its globalization efforts, leading to steady business growth. While enhancing its operations, Fosun has also strengthened its sustainable development management, actively fulfilling corporate social responsibility, improving ESG performance, and leveraging the resources and advantages of its global industrial ecosystem to contribute to a better world.

In recognition of these efforts, the magazine honored Fosun International with three prestigious awards in ESG and sustainability, corporate social responsibility, and branding. These accolades not only acknowledge the growth potential of Fosun's core industries but also reaffirm the Company's dedication to advancing ESG-driven sustainable development.

Fosun's Sustainable Development Strategy: "Create IMPACT"

Looking back on the past, Fosun has always paid attention to the reform and development of the global policies in the field of sustainable development. It has established a comprehensive ESG management system, integrated ESG management requirements into business management over the years, actively responded to national and global strategies in relation to sustainable development, ensured information security, promoted technology innovation, implemented "dual carbon" goals, protected the rights and interests of employees to promote sustainable management and value creation.

Last year, Fosun formulated its sustainable development strategy: "Create IMPACT", which outlines its six key long-term directions: I: Innovation-driven, M: Mindful Operation, P: People and Partner Oriented, A: Advanced Governance, C: Climate and Planet Positive and T: Transparency.

Advancing Global Sustainable Development with Outstanding ESG Performance

Fosun remains committed to its core businesses. By leveraging its increasingly sophisticated global business presence, it has operated responsibly across more than 35 countries and regions, actively contributing to public welfare and creating sustainable value worldwide. Fosun has long been dedicated to philanthropy projects in areas such as rural revitalization, healthcare, educational equity, community construction, culture and art, significantly expanding its impact across global communities and striving to build a more responsible, inclusive and sustainable future.

As a responsible global citizen, Fosun officially joined the United Nations Global Compact ("UN Global Compact") in 2014. It fully supports the ten principles of the UN Global Compact on human rights, labor, environment and anti-corruption, and has deeply integrated these principles into its "Create IMPACT" sustainable development strategy and code of conduct. Over the past year, despite the global environmental, social and economic uncertainties, Fosun remained committed to sustainable development, diligently upholding its long-term commitments in key areas of sustainable development, and achieving good results. Fosun International maintained an MSCI ESG rating of AA, achieved an HSI ESG rating of AA-, ranked in the top 5% among global peers in latest S&P Global's Corporate Sustainability Assessment (CSA), was included in S&P Global's Sustainability Yearbook 2025, and was selected as the top 1% in S&P Global's Sustainability Yearbook 2025 (China Edition).

Fosun for Good: Giving Back to Society

In order to better promote the fulfillment and implementation of corporate social responsibility, Fosun Foundation was established in 2012. It has been making unremitting efforts in the fields of global emergency relief, rural revitalization, healthcare, youth entrepreneurship, education, community development and culture & art, etc. to create social value. Among these initiatives, the Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families since its launch in 2017. Moreover, the "Rural Doctors Program Empowering Rural Medical Services" was included in the "20 Cases of Private Sector's Sustainable Development in China for 20 Years" Report of the UN Global Compact.

Fosun adheres to the innovation-driven strategy and actively facilitates its businesses to achieve innovative results so as to make greater contributions to society. Thanks to the long-term accumulated technology innovation capabilities, Fosun has continued to realize the "world's first" and "China's first" achievements. Henlius' innovative drug, HANSIZHUANG (serplulimab injection), an anti-PD-1 monoclonal antibody, was approved for marketing in the European Union in early 2025. This milestone makes it the first and only PD-1 innovative drug approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the European Union. As of the end of 2024, Fosun Pharma's independently developed artesunate for injection had saved more than 80 million severe malaria patients worldwide, with more than 400 million doses supplied globally.

Regarding youth entrepreneurship and development, under the principle of "Innovation and People-oriented Development", Fosun Foundation, in collaboration with Fidelidade and Portugal's healthcare group Luz Saúde, launched the sustainable innovation project "Protechting Open Innovation Program" in early 2016. Since 2018, Protechting has incubated 40 pilot projects and led to 5 commercial collaborations. On 9 April 2025, the 7th Protechting Open Innovation Program took place in Lisbon, the capital of Portugal, where the top four finalists were announced. In May 2025, these four teams visited Shanghai, Macau, Shenzhen, and Hong Kong for exchanges and roadshows, while also seeking potential business collaboration opportunities. Over the past seven years, Protechting has expanded from Portugal to Europe and now to China and beyond, becoming an international platform for technology innovation exchange that connects young people from different cultures and continents.

Looking ahead, Fosun remains dedicated to advancing its social responsibility through innovation and responsible global operations. Guided by its "Create IMPACT" sustainable development strategy, Fosun will intensify its efforts to build a more responsible, inclusive and sustainable future.

Cision View original content:https://www.prnewswire.com/news-releases/fosun-international-receives-the-esg--sustainability-award-and-two-other-prestigious-honors-from-global-banking-and-finance-review-302478673.html

SOURCE Fosun

FAQ

What awards did Fosun International (FOSUY) receive in 2025 from Global Banking and Finance Review?

Fosun International received three awards: Best Sustainable Development Company Asia 2025, Best CSR Company Asia 2025, and Holding Group Brand of the Year Asia 2025.

What is Fosun International's ESG strategy called and what does it include?

Fosun's ESG strategy is called 'Create IMPACT' and includes six key directions: Innovation-driven, Mindful Operation, People and Partner Oriented, Advanced Governance, Climate and Planet Positive, and Transparency.

How many rural doctors has Fosun's Rural Doctors Program supported since 2017?

The Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families since its launch in 2017.

What significant achievement did Fosun's Henlius achieve in the European Union in 2025?

Henlius' HANSIZHUANG became the first and only PD-1 innovative drug approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the European Union.

What are Fosun International's current ESG ratings and rankings?

Fosun maintains an MSCI ESG rating of AA, an HSI ESG rating of AA-, ranks in the top 5% among global peers in S&P Global's CSA, and was selected as top 1% in S&P Global's Sustainability Yearbook 2025 (China Edition).
Fosun Internatio

OTC:FOSUY

FOSUY Rankings

FOSUY Latest News

FOSUY Stock Data

5.14B
2.44B
Conglomerates
Industrials
Link
Hong Kong
Central